Roux-en-Y gastric bypass (RYGB) is the gold standard bariatric surgical intervention in obese patients with pre-operative gastroesophageal reflux disease (GERD) [1]. Several hypotheses have been proposed to explain GERD recurrence post-operatively, including retained acid-secreting parietal cells in the pouch [2], dysmotility of the Roux limb, and herniation of the gastric pouch through the hiatus. We report the successful treatment of refractory GERD following RYGB using anti-reflux mucosal ablation (ARMA) (Fig. 1).

A 54-year-old woman with a history of RYGB presented with symptoms of GERD, including significant regurgitation and a sour taste in her mouth, which affected her quality of life (GERD-Q score 15). Esophagogastroduodenoscopy revealed a 3-cm hiatal hernia with an American Foregut Society (AFS) hiatus classification of 4 [3], a medium-sized pouch, and a patent gastrojejunostomy. Examination of the gastroesophageal junction revealed loss of an effective flap valve. Wireless capsule pH monitoring revealed a total of 0% acid exposure time, as expected following RYGB. A barium esophagram confirmed a small sliding hiatal hernia with regurgitation. She declined surgical hiatal hernia repair for fear of adverse events. She was offered ARMA for symptom control, to which she agreed (Video 1).

Follow-up endoscopy 4 weeks after ARMA showed significant improvement in the hiatal defect, with an improvement in AFS classification to hiatus grade 1. At 6 months post-ARMA, she reported significant improvement in quality of life (GERD-Q score of 6), with resolution of regurgitation and no dysphagia.

Given the altered anatomy after RYGB, management of refractory GERD can be challenging. Laparoscopic hiatal hernia repair and radiofrequency ablation of the gastroesophageal junction (Stretta procedure) have been reported [4]. Our case demonstrates that ARMA may be an additional therapeutic option. First described by Hernández Mondragón et al. [5] in 2020, ARMA likely exhibits its beneficial effects by remodeling the gastroesophageal junction, leading to decreased proximal gastric distensibility.

Endoscopy_UCTN_Code_TTT_1AO_2AJ
Conflict of Interest

K. Patel is a consultant for Endogastric solutions, Olympus, Boston Scientific.

The authors

Fares Ayoub1, Kalpesh K. Patel1
1 Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, United States

Corresponding author

Fares Ayoub, MD
Section of Gastroenterology and Hepatology, Baylor College of Medicine, 7200 Cambridge St Suite 8B, 77030 Houston, United States
fareswayoub@gmail.com
fares.ayoub@bcm.edu

References


Bibliography

Endoscopy 2024; 56: E37–E38
DOI 10.1055/a-2223-0499
ISSN 0013-726X
© 2024. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Ayoub Fares, Patel Kalpesh K. Anti-reflux mucosal ablation... Endoscopy 2024; 56: E37–E38 | © 2024. The Author(s).